US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
pharma · Relapsing-Remitting Multiple Sclerosis · Spinal Muscular Atrophy
Biogen
Biogen drug portfolio — 28 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
225 Binney Street, Cambridge, MA 02142, US HQ
7,534 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 225 Binney Street, Cambridge, MA 02142, US
- Employees
- 7,534
- Programs
- 0
- Drugs
- 28
- Patents
- 0
Biogen pipeline
Portfolio lens on 28 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Biogen drug portfolio — 28 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Biogen in public FDA and regional records. Molecular target: Inhibitor of nuclear factor kappa-B kinase subunit beta.
- Target
- Inhibitor of nuclear factor kappa-B kinase subunit beta
- Mechanism
- Keap1/Nrf2 inhibitor
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Biogen in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
Musculo-skeletal system (M09)Musculo-skeletal system (M09) compound in Biogen's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
daclizumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-2 receptor.
- Target
- Interleukin-2 receptor
- Mechanism
- Interleukin-2 receptor inhibitor
-
desirudin
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in Biogen's portfolio. Molecular target: Prothrombin.
- Target
- Prothrombin
- Mechanism
- Thrombin inhibitor
-
desloratadine
Respiratory system (R01)US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
dimethyl fumarate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Kelch-like ECH-associated protein 1.
- Target
- Kelch-like ECH-associated protein 1
- Mechanism
- Kelch-like ECH-associated protein 1 inhibitor
-
Development asset linked to Biogen in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
diroximel fumarate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Kelch-like ECH-associated protein 1.
- Target
- Kelch-like ECH-associated protein 1
- Mechanism
- Kelch-like ECH-associated protein 1 inhibitor
-
US regulatory status: approved. Molecular target: Histamine H2 receptor.
- Target
- Histamine H2 receptor
- Mechanism
- Histamine H2 receptor antagonist
-
Development asset linked to Biogen in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
interferon beta-1a
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.
- Target
- Interferon alpha/beta receptor
- Mechanism
- Interferon alpha/beta receptor agonist
-
Development asset linked to Biogen in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
natalizumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Integrin alpha-4/beta-1.
- Target
- Integrin alpha-4/beta-1
- Mechanism
- Integrin alpha-4/beta-7 inhibitor
-
nusinersen
Musculo-skeletal system (M09)Musculo-skeletal system (M09) compound in Biogen's portfolio.
-
US regulatory status: approved. Molecular target: SMN2 pre-mRNA.
- Target
- SMN2 pre-mRNA
- Mechanism
- SMN2 pre-mRNA positive modulator
-
Development asset linked to Biogen in public FDA and regional records. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Anandamide amidohydrolase inhibitor
-
Development asset linked to Biogen in public FDA and regional records.
-
peginterferon beta-1a
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.
- Target
- Interferon alpha/beta receptor
- Mechanism
- Interferon alpha/beta receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved.
-
tofersen
Nervous system (N07)US regulatory status: approved. Molecular target: SOD1 mRNA.
- Target
- SOD1 mRNA
- Mechanism
- SOD1 mRNA inhibitor